TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01865396

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interventional palliative care
Description: Palliative support team will meet the patient soon after diagnosis of incurable disease and will meet the patient at least once a month. The patient will also receive the standard oncologic care.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard oncologic care
Description: Patients will receive standard oncologic care.
Study: NCT02567539

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT with or without radiosensitive therapy
Description: Re-irradiation with hypofractionated intensity modulated radiation therapy (IMRT), using VMAT RapidArc

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiosensitive therapy
Description: Radiosensitive therapy with Temozolomide
Study: NCT00594516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tapentadol (CG5503) Immediate Release IR
Description: 21 day Open Label: an adjustable dose of Tapentadol IR 50-100mg orally every 4-6 hours to maximum total daily dose (TDD) dose of 500 mg during open label period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tapentadol (CG5503) Extended Release (ER)
Description: During 2 double blind periods: Tapentadol ER 100, 150, 200 or 250 mg tablets twice daily in the first intervention period of double-blind phase and Tapentadol IR in the second or Tapentadol IR in first intervention period of double-blind phase and Tapentadol ER in second

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tapentadol (CG5503) Immediate Release (IR)
Description: Following open label period is 2 double blind periods: Tapentadol IR in first intervention period of double-blind phase and Tapentadol ER 100, 150, 200 or 250 mg tablets twice daily in second or Tapentadol ER in first intervention period of double-blind phase and Tapentadol IR in second
Study: NCT03426787

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Aid
Description: Participants will have the option to view a web or paper-based version of the decision aid.
Study: NCT02682225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous placebo
Description: Participants will receive placebo, 40-minute, intravenous infusion on Day 1 of Sequence 1, on Day 2 of Sequence 2, on Day 1 of Period 1 in Sequence 3, 5 and 6, on Day 1 of Period 2 in Sequence 3, 4 and 6, on Day 1 of Period 3 in Sequence 4, 5 and 6, and on Day 1 of Period 4 in Sequence 3, 4 and 5.
Study: NCT01263197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo for LY2216684
Description: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo for LY2216684
Description: administered orally
Study: NCT03998176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bictegravir/emtricitabine/tenofovir alafenamide
Description: B/F/TAF single tablet formulation
Study: NCT04662398

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: JT Device
Description: Shocker giving electrical shocks on testes

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: JT Device
Description: Shocker giving electrical shocks on testes
Study: NCT01191372

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo control
Description: sterile saline for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC19499
Description: Anti-tissue factor pathway inhibitor (TFPI) aptamer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC19499
Description: Anti-tissue factor pathway inhibitor (TFPI) aptamer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC19499
Description: Anti-tissue factor pathway inhibitor (TFPI) aptamer
Study: NCT03662139

Intervention type: OTHER
Intervention: Dynamic Gait Index
Description: Dynamic Gait Index is a clinical tool for assessing functional balance and gait variability in people with neurologic conditions

Intervention type: OTHER
Intervention: Dynamic Gait Index
Description: Dynamic Gait Index is a clinical tool for assessing functional balance and gait variability in people with neurologic conditions
Study: NCT01226823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic Acid
Description: 300 mg capsules 20 mg/kg body weight/day divided in three administrations per day from enrolment until delivery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 300 mg capsules 20 mg/kg body weight/day divided in three administrations per day from enrolment until delivery
Study: NCT01131949

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine
Description: Lamotrigine Tablets (chewable, dispersible), 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Lamotrigine Tablets (chewable, dispersible), 25 mg
Study: NCT04398511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L brevis
Description: Lactobacillus brevis CD2 lozenges (4 billion CFU) after breakfast, lunch and dinner for 21 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo lozenges after breakfast, lunch and dinner for 21 days.
Study: NCT00288977

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Islet Infusion
Study: NCT02598609

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Education program for NICU caregivers
Description: * standardized educational program : learning how to retrospectively analyze causes of a medical error in the NICU in order to prevent it (compulsory)~* implementation of a central line maintenance bundle and checklist, of a central line insertion bundle and checklist and of a daily goals bundle and checklist. (compulsory)~* poster for prevention of extravasation injuries

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Education program for NICU caregivers
Description: * standardized educational program : learning how to retrospectively analyze causes of a medical error in the NICU in order to prevent it (compulsory)~* implementation of a central line maintenance bundle and checklist, of a central line insertion bundle and checklist and of a daily goals bundle and checklist. (compulsory)~* poster for prevention of extravasation injuries

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Education program for NICU caregivers
Description: * standardized educational program : learning how to retrospectively analyze causes of a medical error in the NICU in order to prevent it (compulsory)~* implementation of a central line maintenance bundle and checklist, of a central line insertion bundle and checklist and of a daily goals bundle and checklist. (compulsory)~* poster for prevention of extravasation injuries
Study: NCT02992886

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Preoperative radiation
Description: Radiation treatment before surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltitrexed
Description: concurrent chemotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pelvic surgery
Study: NCT03846739

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin nasal spray
Description: Intranasal administration, 6, 12, or 24 international units (IU) oxytocin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin nasal spray
Description: Intranasal administration, 6, 12, or 24 international units (IU) oxytocin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin nasal spray
Description: Intranasal administration, 6, 12, or 24 international units (IU) oxytocin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The placebo nasal sprays contain identical ingredients except for the peptide itself.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The placebo nasal sprays contain identical ingredients except for the peptide itself.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The placebo nasal sprays contain identical ingredients except for the peptide itself.
Study: NCT01580150

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Berries
Description: Meals containing starch (bread) or sucrose are consumed with berries (150 g) or berry nectars (300 mL).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No berries
Description: Meals containing starch (bread) or sucrose are consumed without berries.
Study: NCT00298168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YSPSL
Description: YSPSL administered intravenously (IV) as a single bolus infusion of 1 mg/kg with 200 mL Lactated Ringer's for Injection USP total volume administered as an ex vivo flush intra-arterially to donor organ prior to implantation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 0.9% normal saline administered IV as a single bolus infusion with 200 mL Lactated Ringer's for Injection USP total volume administered as an ex vivo flush intra-arterially to donor organ prior to implantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YSPSL
Description: YSPSL administered intravenously (IV) as a single bolus infusion of 1 mg/kg with 10 mg YSPSL in 200 mL Lactated Ringer's for Injection USP total volume administered as an ex vivo flush intra-arterially to donor organ prior to implantation
Study: NCT00244972

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipifarnib
Description: Given PO
Study: NCT02464228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipifarnib
Description: oral
Study: NCT00908583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plasmapheresis
Description: Patients will receive plasmapheresis 1.5 x plasma volume prior to each Bortezomib dose. Plasma volume replacement will be per physician discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plasmapheresis
Description: Patients will receive plasmapheresis 1.5 x plasma volume prior to each Bortezomib dose. Plasma volume replacement will be per physician discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plasmapheresis
Description: Patients will receive plasmapheresis 1.5 x plasma volume prior to each Bortezomib dose. Plasma volume replacement will be per physician discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plasmapheresis
Description: Patients will receive plasmapheresis 1.5 x plasma volume prior to each Bortezomib dose. Plasma volume replacement will be per physician discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plasmapheresis
Description: Patients will receive plasmapheresis 1.5 x plasma volume prior to each Bortezomib dose. Plasma volume replacement will be per physician discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Patients will receive bortezomib as described in protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Patients will receive bortezomib as described in protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Patients will receive bortezomib as described in protocol
Study: NCT01263197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo for LY2216684
Description: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo for LY2216684
Description: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo for LY2216684
Description: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo for LY2216684
Description: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo for albuterol
Description: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo for albuterol
Description: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo for albuterol
Description: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo for propranolol
Description: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo for propranolol
Description: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo for propranolol
Description: administered orally
Study: NCT03524976

Intervention type: DEVICE
Intervention: Squid
Description: SQUID™ is injected into the vascular site to be treated, under fluoroscopic control. DMSO dissipates in the blood and causes precipitation of EVOH in which the tantalum powder is trapped. It then forms a consistent spongy embolus.~This embolus solidifies from the outside inwardly while moving distally in the vessel. The non-adhesive character of the embolus allows slow and controlled injections while leaving in place the microcatheter.
Study: NCT01055197

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prophylactic Cranial Irradiation
Description: Prophylactic Cranial Irradiation (PCI) to the brain in ten once-daily fractions of 2.5 Gy, five days per week, for a total of 25 Gy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prophylactic Cranial Irradiation
Description: Prophylactic Cranial Irradiation (PCI) to the brain in ten once-daily fractions of 2.5 Gy, five days per week, for a total of 25 Gy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation Therapy (RT) to locoregional and residual metastatic disease in 15 once daily fractions of 3.0 Gy, 5 days per week, for a total of 45 Gy
Study: NCT01463644

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mepolizumab
Description: This is an anti IL-5 which is given once a month intravenously at the dose of 750 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The placebo will consist of 100 mL normal saline solution (0.9%, 154 mmol/L sodium chloride).
Study: NCT04591613

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Description: Quality of life and chronic disease impact scales will be completed at inclusion and follow-up visits.

Intervention type: OTHER
Group type: OTHER
Intervention: Biocollection
Description: Total serum, plasma samples will be collected

Intervention type: OTHER
Group type: OTHER
Intervention: Follow-up visit
Description: All patients will make an inclusion visit (IV), then a clinical follow-up will be organized for the study at M4, M6, M12 from the day of the onset of the 1st symptoms of COVID.
Study: NCT00908583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Patients will receive bortezomib as described in protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Patients will receive bortezomib as described in protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Patients will receive rituximab as described in protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Patients will receive rituximab as described in protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Patients will receive rituximab as described in protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Patients will receive rituximab as described in protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Patients will receive rituximab as described in protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Each bortezomib dose will be preceded by intravenous methylprednisolone (100mg for first two doses and 50mg for following doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Each bortezomib dose will be preceded by intravenous methylprednisolone (100mg for first two doses and 50mg for following doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Each bortezomib dose will be preceded by intravenous methylprednisolone (100mg for first two doses and 50mg for following doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Each bortezomib dose will be preceded by intravenous methylprednisolone (100mg for first two doses and 50mg for following doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Each bortezomib dose will be preceded by intravenous methylprednisolone (100mg for first two doses and 50mg for following doses).
Study: NCT04110964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAV-hTERT
Description: subjects will receive a single LGT (AAV-hTERT) treatment via IV administration
Study: NCT04434950

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promoting and implementing repeated HIV self-testing and online real-time counseling
Description: At baseline, Month 6 and Month 12, participants will view an online video clip promoting the needs for HIV testing in general and HIV self-testing with online real-time counseling. A free HIV self-testing kit will be sent to participants. An HIVST administrator will provide online real-time pre-test and post-test counseling.
Study: NCT04159766

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NLY01
Description: NLY01, a PEGylated form of the anti-diabetic peptide exenatide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NLY01
Description: NLY01, a PEGylated form of the anti-diabetic peptide exenatide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NLY01
Description: NLY01, a PEGylated form of the anti-diabetic peptide exenatide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: normal saline
Study: NCT02656498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]THK-5351
Description: Imaging for evaluating the accumulation of abnormal tau protein in the brain

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]THK-5351
Description: Imaging for evaluating the accumulation of abnormal tau protein in the brain

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]THK-5351
Description: Imaging for evaluating the accumulation of abnormal tau protein in the brain

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]THK-5351
Description: Imaging for evaluating the accumulation of abnormal tau protein in the brain
Study: NCT00727649

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psyllium powder
Description: 2 teaspoons with 8 ounces of liquid daily for 28 days (weekly adjusted dose)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loperamide
Description: 1 capsule daily for 28 days (weekly adjusted dose)
Study: NCT01326208

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEEP titration
Description: PEEP is set according to the following protocols, respectively, in a randomized order: ARDSnet table, Open Lung strategy, guided by EIT
Study: NCT00984490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin hydrochloride
Description: Metformin: 850 mg orally (PO) twice daily (BID) for 7-21 days, discontinued 24-36 hrs prior to surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Blood and tissue collection to determine the in situ biologic effect of metformin
Study: NCT01025492

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trilipix
Description: 135 mg po daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one tablet po daily
Study: NCT01681628

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Thought Field Therapy.
Description: Thought Field Therapy is a meridian based therapy, where clients tap on specific parts of their body, according to a particular protocol. This does not obliterate the memory of the trauma, but relieves the associated distress.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Thought Field Therapy.
Description: Thought Field Therapy is a meridian based therapy, where clients tap on specific parts of their body, according to a particular protocol. This does not obliterate the memory of the trauma, but relieves the associated distress.
Study: NCT03904745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atosiban
Description: 6,75mg of atosiban will be administered intravenously 30 minutes before embryo transfer
Study: NCT02010606

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic cell vaccination, in addition to standard temozolomide chemotherapy and involved field radiation therapy
Description: Patients will receive a series of four vaccines given weekly during the Induction phase, followed by vaccinations every 8 weeks during the Maintenance phase for as long as patients remain on the study or until the vaccine supply is depleted. In addition to the investigative treatment, patients with newly diagnosed glioblastoma will receive standard temozolomide chemotherapy and radiation treatment, with the vaccine Induction phase beginning at the conclusion of radiation.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic cell vaccination, with optional bevacizumab treatment for patients previously treated with bevacizumab
Description: Patients will receive a series of four vaccines given weekly during the Induction phase, followed by vaccinations every 8 weeks during the Maintenance phase for as long as patients remain on the study or until the vaccine supply is depleted. Patients with recurrent glioblastoma will not receive additional treatment other than the investigative treatment as long as they remain on study, unless they were previously treated with bevacizumab, in which case they will be allowed to continue receiving bevacizumab
Study: NCT03222739

Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasound
Description: An industry standard ultrasound will be fitted with a self-tracking probe to track along the spine. The ultrasound will be performed three (3) times along the spine at initial consultation for scoliosis.
Study: NCT00227565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation
Study: NCT02636933

Intervention type: OTHER
Intervention: Lung Function Assessment
Description: Lung Function Assessment

Intervention type: OTHER
Intervention: Lung Function Assessment
Description: Lung Function Assessment